| Indication |
For the reduction of elevated intraocular pressure in patients
with open angle glaucoma or ocular hypertension who are intolerant of
other intraocular pressure lowering medications or insufficiently
responsive (failed to achieve target IOP determined after multiple
measurements over time) to another intraocular pressure lowering
medication. |
| Pharmacodynamics |
Bimatoprost is a prostamide, a synthetic structural analog of
prostaglandin with ocular hypotensive activity, that is chemically
related to prostamide F. It selectively mimics the effects of naturally
occurring substances, prostamides. Bimatoprost lowers intraocular
pressure (IOP) in humans. Elevated IOP presents a major risk factor for
glaucomatous field loss. The higher the level of IOP, the greater the
likelihood of optic nerve damage and visual field loss. |
| Mechanism of action |
Bimatoprost is believed to lower intraocular pressure (IOP) in
humans by increasing outflow of aqueous humor through both the
trabecular meshwork and uveoscleral routes. Bimatoprost reduces the
pressure in the eye by mimicking the action of a naturally-occuring
prostaglandin. Prostaglandins are a group of chemicals found in many
places in the body. In the eye, they increase the drainage of the
aqueous humour out of the eyeball. Bimatoprost is a synthetic compound
related to one of the natural prostaglandins, and works by increasing
the drainage of aqueous humour out of the eyeball. Bimatoprost may also
lower the rate of aqueous formation in the eye. Both these effects
decrease the pressure within the eye. |
| Absorption |
Systemically absorbed when administered to the eye. |
| Volume of distribution |
|
| Protein binding |
Approximately 88% of bimatoprost is bound in human plasma. |
| Metabolism |
Bimatoprost undergoes oxidation, N-deethylation and glucuronidation to form a variety of metabolites. |
| Route of elimination |
Up to 67% of the administered dose was excreted in the urine while 25% of the dose was recovered in the feces. |
| Half life |
Elimination half-life is approximately 45 minutes. |
| Clearance |
- 1.5 L/hr/kg [Healthy subjects receiving IV administration of 3.12 ug/kg]
|
| Toxicity |
In oral (by gavage) mouse and rat studies, doses up to 100 mg/kg/day did not produce any toxicity. This dose expressed as mg/m2 is at least 70 times higher than the accidental dose of one bottle of bimatoprost for a 10 kg child. |
Comments
Post a Comment